What peptide therapy is and how it works
Peptides are short amino acid chains that function as signalling molecules in the body - instructing tissues to repair, hormones to be released, appetite to be suppressed, or immune responses to be modulated. Therapeutic peptide programs use these molecules either to replace declining endogenous peptide activity (as in growth hormone optimization) or to activate specific biological pathways at clinically meaningful levels (as in GLP-1 weight management).
The practical advantage of peptides over many synthetic drugs is target specificity: a peptide designed to activate a single receptor type tends to interact with that receptor and not much else. This contributes to the favorable tolerability profile seen with many peptide classes - though it is not a guarantee of safety, and FDA-approved peptides still carry meaningful side effect profiles that require physician monitoring.
Most therapeutic peptides are administered by subcutaneous self-injection, typically once daily or weekly. Oral and intranasal formulations exist for some compounds. The injection route is necessary for most peptides because they would be broken down in the digestive system before reaching the bloodstream in meaningful concentrations.
The FDA landscape in 2026: what changed and why it matters
The regulatory environment for US peptide therapy shifted substantially in 2024, with effects still rippling through clinic offerings in 2026.
The compounded semaglutide and tirzepatide chapter: During 2022-2024, both semaglutide and tirzepatide were on the FDA's drug shortage list, which legally permitted compounding pharmacies to produce versions of these drugs. This created a large market of telehealth clinics offering compounded GLP-1s at $150-400/month compared to $1,000+ for branded versions.
In 2024-2025, the FDA formally removed semaglutide and tirzepatide from the shortage list (though the timeline and legal battles around this were complex). Without active shortage status, large-scale compounding is no longer straightforwardly permitted. Patient-specific 503A compounding with documented clinical justification can still occur, but the broad availability of compounded GLP-1s through any telehealth clinic is under ongoing legal and regulatory scrutiny. See our detailed guide to compounded peptides and what you need to know.
The bulk substance category list: In 2024, the FDA finalized its categorization of peptides used in compounding under the bulk substance nomination process:
- Category II (cannot be compounded): BPC-157 was placed here, meaning compounding pharmacies cannot legally produce it for patient use under current rules. Clinics still advertising BPC-157 as a standard offering should be asked specifically how they navigate current regulations.
- Category III (under further review): Several other peptides remain in regulatory limbo pending further FDA review. This category does not mean legal - it means the FDA has not yet made a final determination.
- Not nominated or approved as bulk substances: The majority of compounded peptides beyond semaglutide and tirzepatide were never nominated and occupy uncertain legal ground.
The practical effect: the menu of peptides available through licensed US compounding pharmacies is narrower in 2026 than it was in 2022. What remains legally accessible requires physician practices that have thought carefully about which pharmacies they work with and why. For a full breakdown of current legal status by peptide, see what peptides are legal in the US in 2026.
Treatment categories: what is actually available through physician programs
Weight loss and metabolic health (GLP-1 peptides)
This is the largest and most clinically validated category. FDA-approved options:
- Semaglutide (Ozempic, Wegovy): Ozempic approved for type 2 diabetes, Wegovy for chronic weight management in adults with BMI 30+ or 27+ with a weight-related condition. The STEP trials showed average weight loss of 15-17% over 68 weeks at the Wegovy dose.
- Tirzepatide (Mounjaro, Zepbound): Dual GLP-1/GIP agonist. Mounjaro approved for type 2 diabetes, Zepbound for chronic weight management. The SURMOUNT trials showed average weight loss of 20-22% over 72 weeks.
- Liraglutide (Saxenda, Victoza): Earlier-generation GLP-1. Effective but less potent than semaglutide or tirzepatide; less commonly prescribed as a first-line choice where the newer drugs are accessible.
These are the most accessible peptide-adjacent medicines in the US in 2026. Telehealth access is widespread. See telehealth peptide clinics in the US for how remote access programs work.
Growth hormone optimization
This category uses growth hormone-releasing peptides and analogues to stimulate the pituitary gland's endogenous GH production - a different approach from synthetic HGH injection, which is tightly controlled.
- Tesamorelin (Egrifta): FDA-approved for HIV-associated lipodystrophy; used off-label by physicians for GH optimization in other patient populations. The only FDA-approved peptide in this category.
- Sermorelin, CJC-1295, Ipamorelin: Compounded growth hormone secretagogues that were widely used before 2024 rule changes. Access continues through physicians who work with compounding pharmacies navigating current FDA rules, though availability is not universal.
Tissue repair and recovery
This was the area most affected by the 2024 FDA bulk substance changes:
- BPC-157: Classified FDA Category II (cannot be compounded under current rules). Has a significant preclinical evidence base for gut healing, tendon repair, and neuroprotection - but no completed human clinical trials. Clinics that still offer it should be transparent about regulatory compliance.
- TB-500 (Thymosin Beta-4 fragment): Similar regulatory situation to BPC-157. Compelling animal study data; limited human clinical evidence.
- Thymosin Alpha-1 (TA-1): Approved in many other countries (marketed as Zadaxin); not FDA-approved in the US. Used off-label by some physicians for immune modulation.
Sexual health
- Bremelanotide / PT-141 (Vyleesi): FDA-approved for hypoactive sexual desire disorder in premenopausal women. Also used off-label by physicians for other patients.
What physician supervision involves and why it matters
A legitimate program in any category follows the same clinical structure:
- 1Full medical intake - health history, medications, allergies, treatment goals
- 2Baseline lab work relevant to the treatment category
- 3A real physician consultation - not an automated approval
- 4A prescription from a licensed US physician, NP, or PA
- 5Dispensing through a licensed US pharmacy (503A or 503B accredited for compounded medications)
- 6Structured follow-up - scheduled appointments, repeat labs, accessible contact
The supervision is what separates clinical outcomes from the risks of self-administered research chemicals. It is also how dose-dependent side effects are caught early, contraindications are identified before harm occurs, and the program is adjusted as your response evolves.
For help evaluating specific clinics, see how to find a physician-supervised peptide clinic in the US.
What peptide therapy costs in the US in 2026
Costs vary by treatment category and access method:
| Program type | Typical monthly cost |
|---|---|
| Branded Wegovy / Zepbound (with insurance) | $0-200 if covered |
| Branded Wegovy / Zepbound (without insurance) | $1,000-1,400 |
| Compounded semaglutide via telehealth | $150-400 |
| Compounded tirzepatide via telehealth | $200-500 |
| Growth hormone peptide programs | $200-500 |
| Recovery peptide programs (where available) | $150-350 |
| PT-141 / sexual health programs | $100-300 per cycle |
These figures exclude the initial consultation fee (typically $75-200) and any lab work costs (typically $100-300 depending on the panel). Some clinics bundle consultation, labs, and first-month medication into a single entry package. For detailed cost guidance, see the cost of peptide therapy in the US.
Telehealth access: how most US patients now access peptide programs
The telehealth expansion of 2020-2022 permanently shifted how most Americans access physician-supervised care, including peptide therapy. The majority of GLP-1 programs, growth hormone programs, and many recovery peptide programs are now offered entirely via telehealth.
Key things to verify for any telehealth program:
- The clinic is licensed to prescribe in your state (telehealth prescribing is state-by-state)
- The consultation is a real medical appointment with a named, licensed prescriber
- Lab work is ordered or reviewed before any prescription decision
- The medication is dispensed by a licensed US pharmacy, not shipped from overseas
How to start
Finding the right physician-supervised program involves comparing clinics on the dimensions that actually matter - treatment focus, physician involvement, telehealth availability, pharmacy quality, and cost transparency. Browse the Peptide Finder US directory to compare options in your state or filter by treatment goal.
State directories: Texas - California - Florida - New York - Colorado - Arizona - browse all states
Related guides: What is peptide therapy? - Are peptides safe? - How to get a peptide prescription - What peptides are legal in the US in 2026
---
*This article is for educational purposes only. Consult a licensed physician before starting any peptide therapy program.*